Form 4: Pennant Group Executive Sells Shares
Insider Transaction (Form 4)
Jason Paul Steik, Chief Clinical Officer of Pennant Group, Inc., sold 1,394 shares of common stock on August 6, 2026 for $38.52 per share.
Summary
- Open-market sale: disposed of 1,394 Common Stock at $38.52 ($53,700) on August 6, 2026; holds 15,106 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $53,700 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jason Paul Steik — Officer (Chief Clinical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-06 | Open-market sale | Common Stock | 1,394 | $39 | $53.7K | 15,106 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-06 | Open-market sale (1,394 shares) |
Keywords
insider transaction, Form 4, PNTG, Pennant Group, Inc., bearish, Jason Paul Steik
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.